Effect of S-adenosylmethionine tablets on the reduction of age-related mental decline in dogs: A double-blinded, placebo-controlled trial

Veterinary Therapeutics

Volumn 9, Issue 2, 2008, Pages 69-82

  Reme C A ^a   Dramard, V ^b   Kern, L ^c   Hofmans, J ^d   Halsberghe, C ^e   Vida Mombiela, D ^f  

^a Virbac SA   (France)

^b Veterinary Behavior Referrals   (France)

^c Veterinary Behavior Referrals   (France)

^d Poble Sec Veterinary Centre ^*  (Belgium)

^e Veterinary Clinic   (Belgium)

^f EAP Poble Sec   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

S ADENOSYLMETHIONINE;

AGING; ANIMAL; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; FEMALE; LOCOMOTION; MALE; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGING; ANIMALS; COGNITION DISORDERS; DOG DISEASES; DOGS; FEMALE; LOCOMOTION; MALE; S-ADENOSYLMETHIONINE; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 48049094157     PISSN: 15283593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Landsberg G, Araujo JA. Behavior problems in geriatric pets. Vet Clin North Am Small Anim Pract 2005;35:675-698.
2. Chapman BL, Voith VL. Behavioral problems in old dogs: 26 cases ( 1984-1987). JAVMA 1990;196:944-946.
3. Ruehl WW, Hart BL. Canine cognitive dysfunction. In: Dodman NH, Shuster L, eds. Psychopharmacology of Animal Behavior Disorders. Hoboken, NJ: Blackwell Science; 1998:283-304.
4. Bain MJ, Hart BL, Cliff KD, Ruehl WW. Predicting behavioral changes associated with age-related cognitive impairment in dogs. JAVMA 2001;218:1792-1795.
5. Neilson JC, Hart BL, Cliff KD, Ruehl WW. Prevalence of behavioral changes associated with age-related cognitive impairment in dogs. JAVMA 2001;218:1787-1791.
6. Kahler S. Chronic dysfunction syndrome among manageable behavioral problems. JAVMA 2005;227: 863-864.
7. Cummings BJ, Su JH, Cotman CW, et al. β-Amyloid accumulation in aged canine brain: a model of early plaque formation in Alzheimer's disease. Neurobiol Aging 1993;14:547-560.
8. Borras D, Ferret I, Pumarola M. Age-related changes in the brain of the dog. Vet Pathol 1999;36:202-211.
9. Bottiglieri T. S-adenosyl-L-methionine (SAMe): from the bench to the bedside-molecular basis of a pleiotropic molecule. Am J Clin Nutr 2002;76,1151S-1157S.
10. Papakostas GI, Alpert JE, Fava M. S-adenosyl-methionine in depression: a comprehensive review of the literature. Curr Psychiatry Rep 2003;5:460-466.
11. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr 2002;76:1158S-1161S.
12. Nguyen M, Gregan A. S-adenosylmethionine and depression. Aust Fam Physician 2002;31:339-343.
13. Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994;45:137-152.
14. Bottiglieri T, Hyland K. S-adenosylmethionine levels in psychiatric and neurological disorders: a review. Acta Neurol Scand 1994; 154:19-26.
15. Morrison LD, Smith DD, Kish SJ. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J Neurochem 1996;67:1328-1331.
16. Bottiglieri T, Godfrey P, Flynn T, et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 1990;53: 1096-1098.
17. Reynolds EH, Godfrey P, Bottiglieri T, et al. S-adenosylmethionine and Alzheimer's disease. Neurology 1989;39(Suppl 1):397.
18. Fontanari D, DiPalma C, Giorgetti G, et al. Effects of S-adenosyl-L-methionine on cognitive and vigilance functions in the elderly. Curr Ther Res Clin Exp 1994;55: 682-689.
19. Milgram NW, Head E, Weiner E, Thomas E. Cognitive functions and aging in the dog: acquisition of non-spatial visual tasks. Behav Neurosci 1994;108:57-68.
20. Tapp PD, Siwak CT, Estrada J, et al. Size and reversal learning in the beagle dog as a measure of executive function and inhibitory control in aging. Learn Mem 2003;10:64-73.
21. Milgram NW, Head EA, Zicker SC, et al. Long term treatment with antioxidants and a program of behavioral enrichment reduces age-dependant impairment in discrimination and reversal learning in beagle dogs. Exp Gerontol 2004;39:753-765.
22. Ruehl WW, Bruyette DS, De Paoli A, et al. Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to l-deprenyl therapy. Prog Brain Res 1995;106:217-225.
23. Milgram NW, Zicker SC, Head EA, et al. Dietary enrichment counteracts age-associated cognitive dysfunction in canines. Neurobiol Aging 2002;23:737-745.
24. Araujo J, Landsberg GM, Milgram NW, Miolo A. Improvement of short term memory performance in aged beagles by a neutraceutical supplement containing phosphatidylserine, Ginkgo biloba, vitamin E and pyridoxine. Can Vet J 2008;49:379-385.
25. Gingerich DA, Strobel JD. Use of client-specific outcome measures to assess treatment effects in geriatric, arthritic dogs: controlled clinical evaluation of a nutraceutical. Vet Ther 2003;4:56-66.
26. Torta R, Borio R, Cicolin A, et al. S-adenosyl-L-methionine normalizes P300 latency in patients with major depression. Curr Ther Res Clin Exp 1994;55:864-874.
27. Saletu B, Anderer P, Linzmayer L, et al. Pharmacodynamic studies on the central mode of action of S-adenosyl-L-methionine (SAMe) infusions in elderly subjects, utilizing EEG mapping and psychometry. J Neural Transm 2002;109:1505-1526.
28. Arnold O, Saletu B, Anderer P, et al. Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry. Eur Neuropsychopharmacol 2005;15:533-543.
29. Saletu B, Anderer P, Di Padova C, et al. Electrophysiological neuroimaging of the central effects of S-adenosyl-L-methionine by mapping of electroencephalograms and event-related potentials and low-resolution brain electromagnetic tomography. Am J Clin Nutr 2002;76(Supplement): 1162S-1171S.
30. Bressa GM. S-adenosyl-l-methionine (SAMe) as anti-depressant: meta-analysis of clinical studies. Acta Neural Scand 1994;154(Supplement):7-14.
31. Delle Chiaie R, Pancheri R, Scapicchio P. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methione 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentre studies. Am J Clin Nutr 2002;76(Suppl): 1172S-1176S.
32. Curcio M, Catto E, Stramentinoli G, Algeri S. Effect of S-adenosyl-L-methionine on serotonin metabolism in rat brain. Prog Neuropsychopharmacol 1978;2:65-71.
33. Algeri S, Catto E, Curcio M, Coll E. Changes in rat brain noradrenaline and serotonin metabolism after administration of S-adenosylmethionine. In: Zappia V, Usdin E, Salvatore S, eds. Biochemical and Pharmacological Roles of Adenosylmethionine and the Central Nervous System. New York, NY: Pergamon Press; 1979:81-87.
34. Otero-Losada ME, Rubio MC. Acute changes in 5-HT metabolism after S-adenosy-L-methionine administration. Gen Pharmacol 1989;20:403-406.
35. Otero-Losada ME, Rubio MC. Acute effects of S-adenosylmethionine on catecholaminergic central functions. Eur J Pharmacol 1990;163:353-356.
36. Cimino S, Vantini G, Algeri S, et al. Age-related modification of dopaminergic and β-adrenergic receptor system: restoration to normal activity by modifying membrane fluidity with S-adenosylmethionine. Life Sci 1984;34:2029-2039.
37. Cohen BM, Stramentinoli G, Sosa AL, et al. Effects of a novel antidepressant S-adenosyl-methionine on α1- and β-adrenoreceptors in rat brain. Eur J Pharmacol 1989; 170:201-207.
38. Muccioli G, Scordamaglia A, Bertacco S, Di Carlo R. Effects of S-adenosyl-L-methionine on brain muscarinic receptors of aged rats. Eur J Pharmacol 1992;227:293-299.
39. Muccioli G, Di Carlo R. S-adenosyl-L-methionine restores prolactin receptors in the aged rabbit brain. Eur J Pharmacol 1989;166:223-230.
40. Di Padova C. S-adenosylmethionine in the treatment of osteoarthritis, review of the clinical studies. Am J Med 1987;83:60-65.
41. König B. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis. Am J Med 1987;83:89-94.
42. Müller-Fassbender H. Double-blind clinical trial of S-adenosylmethionine versus ibuprofen in the treatment of osteoarthritis. Am J Med 1987;83:81-83.
43. Naim WI, Reinsch S, Hoehlet F, et al. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. BMC Musculoskelet Disord 2004;26:5-6.
44. Stramentinoli G. Pharmacologic aspects of S-adenosylmethionine. Pharmacokinetics and pharmacodynamics. Am J Med 1987;83(Suppl 5A):35-42.
45. Barcelo HA, Wiemeyer JC, Sagasta CL, et al. Effect of S-adenosylmethionine on experimental osteoarthritis in rabbits. Am J Med 1987;83(Suppl 5A):55-59.
46. Gutierrez S, Palacios I, Sanchez-Pernaute O, et al. SAMe restores the changes in the proliferation and in the synthesis of fibronectin and proteoglycans induced by tumour necrosis factor alpha on cultured rabbit synovial cells. Br J Rheumatol 1997;36:27-31.